FDA clears device for prolonged ECMO, another for faster deployment
Click Here to Manage Email Alerts
Abbott announced FDA clearances for two components of the company’s life support system.
The CentriMag blood pump is now indicated for use with the CentriMag system for longer-term use in adults requiring extracorporeal membrane oxygenation (ECMO), allowing more time to assess next steps in the care for critically ill patients, according to a company release.
Image: Adobe Stock
The pump is now cleared for providing longer-term life support for more than 6 hours through ECMO.
The company also received FDA clearance for its new prepackaged system with several pre-connected components that could accelerate the deployment of the life support system.
The pre-connected pack received FDA clearance for urgent cardiopulmonary support lasting less than 6 hours.
“Life support technology is a critical tool for physicians as we assess next steps for our sickest patients. The need for long-term support from systems like the Abbott CentriMag pump was vital during the COVID-19 pandemic,” Antone Tatooles, MD, cardiothoracic surgeon at Advocate Christ Hospital and Medical Center in Oak Lawn, Illinois, said in the release.
Collapse
Click Here to Manage Email Alerts